Positron Emission Tomography (PET) imaging in head and neck cancer;La tomografía por emisión de positrones (PET) en la patología oncológica de cabeza y cuello

Acta Otorrinolaringologica Espanola

Volumn 55, Issue 7, 2004, Pages 303-309

  Suarez Fernandez J P ^a   Maldonado Suarez A ^a   Dominguez Grande M L ^b   Santos Ortega, M ^c   Rodriguez Villalba S ^c   Garcia Camanaque L ^a   Resino, M C ^a   Pozo Garcia M A ^a  

^a Instituto Tecnologico PET   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Head and neck cancer; PET; Prognosis; Recurrence; Staging; Therapy monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; METASTASIS; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; TUMOR RECURRENCE; ALGORITHM; HEAD AND NECK TUMOR; PATHOLOGY; SCINTISCANNING;

ALGORITHMS; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 16644372281     PISSN: 00016519     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-6519(04)78527-1     Document Type: Review

References (35)

1. Lowe VJ, Stack BC Jr. PET imaging in head and neck cancer. En: Valk PE, Bailey DL, Townsend DW, Maisey MN (Eds): Positron Emission Tomography: basic science and clinical practice, Springer-Verlag London Limited (UK); 535-46.
2. Fukui MB, Blodgett TM, Meltzer CC. PET/CT imaging in recurrent head and neck cancer. Semin Ultrasound CT MR 2003; 24: 157-63.
3. Popperl G, Lang S, Dagdelen O, Jager L, Tiling R, Hahn K, et al. Correlation of FDG-PET and MRI/CT with histopatology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2002; 174: 714-20.
4. Hannah A, Scott AM, Tochon-Danguy H, Chan JG, Akhurst T, Berlangieri S, et al. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002; 236: 208-17.
5. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S. Is there a role for FDGPET in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma? Head Neck 2002; 24: 345-9.
6. Myers LL, Wax MK. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer. J Otolaryngol 1998; 27: 342-7.
7. Johansen J, Eigtved A, Buchwald C, Theilgaard SA, Hanne S, Hansen HS. Implication of 18FFluoro-2-Deoxy-D-Glucose Positron Emission Tomography on Management of Carcinoma of Unknown Primary in the Head and Neck: A Danish Cohort Study. Laryngoscope 2002; 112: 2009-14.
8. AAssar OS, Fischbein NJ, Caputo GR, Kaplan MJ, Price DC, Singer MI, et al. Metastatic head and neck cancer: role and usefullness of FDG-PET in locating occult primary tumors. Radiology 1999; 210: 177-81.
9. Braams JW, Pruim J, Kole AC, Nikkels PG, Vaalburg W, Vermey A, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997; 26: 112-15.
10. Mendenhall WM, Manusco AA, Parsons JT, Stringer SP, Cassisi NJ. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck 1998; 20: 739-44.
11. Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003; 44: 1301-14.
12. Kitagawa Y, Nishizawa S, Sano K, Sadato N, Maruta Y, Ogasawara T, et al. FDG-PET in patients with head and neck tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 207-7.
13. Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Presented at the 5th International Conference on Head and Neck Cancer, San Francisco, California, July 29-August 2, 2000. Head Neck 2001; 23: 1056-60.
14. Schwartz DL, Rajendran J, Yueh B, Coltrera M, Anzai Y, Krohn K, et al. Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg 2003; 129: 1173-8.
15. Lowe VJ, Boyd JH, Dunphy FR, Kim H, Dunleavy T, Collins BT, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18: 651-8.
16. Greven KM, Williams D, Ketes JJ, McGuirt WF, Watson NJ, Case LD. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer? Cancer J Scientific Amer 1997; 3: 353-7.
17. Li P, Zhuang H, Mozley PD, Denittis A, Yeh D, Machtay M, et al. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med 2001; 26: 131-5.
18. Terhaard CH, Bongers V, Van Rijk PP, Hordijk GJ. F-18-fluoro-deoxy- glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/ pharyngeal cancer. Head Neck 2001; 23: 933-41.
19. Kao CH, Shiau YC, Shen YY, Yen RF. Detection of recurrent or persitent nasopharyngeal carcinomas after radiotherapy with Tc-MIBI and CT. Cancer 2002; 94: 1981-6.
20. Tsai MH, Shiau YC, Kao CH, Shen YY, Lin CC, Lee CC. Detection of recurrent nasopharyngeal carcinomas with positron emission tomography using 18-fluoro-2-deoxyglucose in patients with indeterminate magnetic resonance imaging findings after radiotherapy. J Cancer Res Clin Oncol 2002; 128 :279-82.
21. Conessa C, Clement P, Foehrenbach H, Maszelin P, Verdalle P, Kossowski M, et al. Rev Laryngol Otol Rhinol (Bord) 2001; 122: 253-8.
22. Greven KM, Williams DW, McGuirt WF, Harkness BA, D'Agostino RB, Keyes JW, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001; 23: 942-6.
23. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004; 45: 56-68.
24. Perie S, Montravers F, Kerrou K, Angelard B, Tassart M, Talbot JN, et al. Fluorodeoxyglucose imaging using a coincidence gamma camera to detect headand neck squamous cell carcinoma and response to chemotherapy. Ann Otol Rhinol Laryngol 2002; 111: 763-71.
25. Lowe VJ, Dunphy F, Varvares M, Kim H, Wittry M, Dunphy CH, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using FDGPET. Head Neck 1997; 19: 666-74.
26. Giannopoulou C. The role of SPET and PET in monitoring tumor response to therapy. Eur J Nucl Med Mol Imaging 2003; 30: 1173-1200.
27. Nishioka T, Shiga T, Shirato H, Tsukamoto E, Tsuchiya MDK, Kato T, et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 2002; 53: 1051-7.
28. Zimny M, Wildberger JE, Cremerius U, DiMartino E, Jaenicke S, Nowak B, et al. Combined image interpretation of computed tomography and hybrid PET in head and neck cancer. Nuklearmedizin 2002; 41: 14-21.
29. Mutic S, Malyapa RS, Grigsby PW, Dehdashti F, Miller TR, Zoberi I, et al. PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes-a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys 2003; 55: 28-35.
30. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003; 57: 853-63.
31. Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N, et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 2003; 30: 63-71.
32. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002; 86: 512-6.
33. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El Ghazi el A, Lehmann W, et al. Standardized uptake value of 2-[(18)f] fluoro-2-deoxy-d-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20:1398-404.
34. Kunkel M, Forster GJ, Reichert TE, Kutzner J, Benz P, Bartenstein P, et al. Radiation response non-invasively imaged by [(18)F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol 2003; 39: 170-7.
35. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 2004; 31: 5-12.